The course of dry eye after phacoemulsification surgery

Servet Cetinkaya¹,⁶*, Emine Mestan², Nursen Oncel Acir³, Yasemin Fatma Cetinkaya⁴, Zeynep Dadaci³ and Halil Ibrahim Yener⁵

Abstract

Background: The aim of this retrospective study was to evaluate the course of dry eye syndrome after phacoemulsification surgery.

Methods: One hundred and ninety-two eyes of 96 patients (30 males, 66 females) with chronic dry eye syndrome and cataract, who had undergone phacoemulsification surgery were enrolled in this study.

Results: Their mean age was 68.46 ± 8.14 standard deviation (SD) (range 56–83) years. Thirty of them (31 %) were males and 66 (69 %) were females. Ocular Surface Disease Index (OSDI) questionnaire scores increased postoperatively, but arrived preoperative levels at the end of 3rd month following the surgery. Fluorescein staining patterns according to Oxford Schema got worse postoperatively, however after postoperative 3rd month they got better and resembled preoperative patterns. The mean postoperative 1st day, 1st week and 1st month Break-up Time (BUT) values were significantly lower than preoperative BUT value (P<0.001, P<0.001, P<0.001), however 3rd month, 6th month, 1st year and 2nd year values were not significantly different from preoperative value (P=0.441, P=0.078, P=0.145, P=0.125).

The mean postoperative 1st day, 1st week and 1st month Schirmer Test 1 (ST1) values were significantly lower than preoperative ST1 value (P<0.001, P<0.001, P<0.001), however 3rd month, 6th month, 1st year and 2nd year values were not significantly different from preoperative value (P=0.748, P=0.439, P=0.091, P=0.214).

Conclusion: Phacoemulsification surgery may aggravate the signs and symptoms of dry eye and affect dry eye test values in chronic dry eye patients in short-term. However, in long-term, signs and symptoms of dry eye decrease and dry eye test values return to preoperative values.

Keywords: Phacoemulsification, Dry eye, Break-up Time, Schirmer

Background

Dry eye syndrome is a multifactorial disease characterized by dryness of the ocular surface due to tear deficiency and overevaporation [1, 2]. There are many causes and factors leading to dry eye, including aging, female gender, connective tissue diseases, Diabetes Mellitus, systemic hypertension, contact lens usage, drugs like antihistaminies, anticholinergics, antidepressants, oral contraceptives and topical eye drops containing preservatives and ocular diseases like blepharitis, chronic conjunctivitis, meibomitis and pterygium [3–5]. The symptoms observed in dry eye syndrome include dryness, irritation, burning, foreign body sensation, heaviness of the eyelids, redness, reflex lacrimation, ocular pain and fatigue. It may cause punctate keratitis, persistent epithelial defect, filamentary keratopathy, superior limbic keratoconjunctivitis and reduced visual acuity [6, 7].

Some surgical interventions related to anterior segment may also cause dry eye and aggravate the symptoms in pre-existing dry eye, like PRK, LASIK and cataract surgery [8–10].

In this study, we evaluated the course of dry eye syndrome after phacoemulsification surgery.

Methods

The study protocol was approved by the local ethics committee (Selcuk University, Faculty of Medicine Ethics Commitee, Konya, Turkey). An informed written consent
was obtained from the patients for the cataract surgery. The study was carried out according to the tenets of the Declaration of Helsinki.

One hundred and ninety-two eyes of 96 patients with chronic dry eye syndrome and cataract were enrolled in this study. They had undergone uneventful phacoemulsification and IOL implantation operation between January 2010 and March 2011. Their medical records were evaluated retrospectively. Their mean age was 68.46 ± 8.14 (SD) (56–83) years. Thirty of them (31 %) were male and 66 (69 %) were female. They all had bilateral cataracts. All of the surgeries were performed by a single surgeon (SC). Under subtenon anesthesia, a 2.75 mm clear corneal incision was made. Anterior chamber was filled with a dispersive (hydroxypropylmethylcellulose, Easy Visc, Germany) viscoelastic substance. After continuous curvilinear capsulorhexis, hydrodissection and hydrodelineation was performed, then a sideport entrance was made. The nucleus was removed by using the “divide and conquer” technique (Sovereign Compact, Phacoemulsification System, AMO, USA). The cortex was aspirated with coaxial irrigation/ aspiration. The capsular bag was filled with a cohesive (Na Hyaluronate 1.6, Easyluron, Germany) viscoelastic substance. A foldable monofocal posterior chamber IOL (Acrriva, VSY, Turkey) was implanted in the capsular bag through an injector system. The viscoelastic material was aspirated completely. The entrances were closed with stromal hydration. After the operation patients used topical antibiotic (Moxifloxacin 0.5 %, Vigamox, Alcon, USA) four times a day for a week and topical steroid (Dexamethasone Na Phosphate 0.1 %, Dexa-sine SE, Liba, USA) six times a day for a week and tapered for subsequent 3 weeks. These two eyedrops did not contain any preservatives. They were all taking artificial tears therapy routinely and 12 of them (12 %) were taking additional topical cyclosporin A. Their therapies were not interrupted due to the surgery. Their full ophthalmological examinations were performed 1 week before the surgery and 1st day, 1st week, 1st month, 3rd month, 6th month, 1st year and 2nd year after the surgery and additionally fluorescein staining, BUT and ST1 without anesthesia were performed owing to the chronic dry eye. OSDI questionnaire was applied 1 week before the surgery and 1st day, 1st week, 1st month and 6th month after the surgery.

OSDI score was calculated by this formula: Total points of all answered questions x 100/Total number of answered questions x 4. The range of OSDI scores is between 0 and 100. Scores over 25 shows dry eye syndrome. Fluorescein staining was classified according to Oxford Schema (Grade 0 to 5). Grade 2 and greater than this level indicate dry eye syndrome. For BUT, a fluorescein strip was placed in the inferior fornix and the patient was asked to blink several times and with slit lamp biomicroscopy by using cobalt blue filter, the interval between last blink and first appearance of a dry spot or tear film break-up was recorded, and this was repeated three times and the average was determined. Values shorter than 10 s indicate dry eye syndrome. For ST1, Schirmer strip was inserted into the inferior fornix beneath the temporal lid margin, after 5 min, strip was removed and the wetness was measured. Values lower than 5 mm are diagnostic for dry eye syndrome.

Statistical analysis
For statistical analysis, SPSS version 22 programme was used. For comparison of the data, Chi-square test and Paired t test were used. A P<0.05 value was accepted as statistically significant.

Results
The time of dry eye diagnosis of these patients was approximately 1 to 5 years prior to the surgery. During the time of diagnosis at the first examination, all of the patients had complaints such as burning, stinging, redness, dryness, foreign body sensation, pain and fatigue in their eyes. OSDI scores were between 25 and 30 in 6 (6 %) patients. Fluorescein staining pattern, BUT and ST1 tests were performed. Twenty-four eyes (12 %) had grade 4, 42 eyes (22 %) had grade 3, 66 eyes (34 %) had grade 2 and 60 eyes (31 %) had grade 1 staining pattern according to Oxford Schema. BUT values were under 10 s in 138 eyes (72 %) and under 5 s in 54 eyes (28 %). ST1 values were under 5 mm in 150 eyes (78 %) and under 3 mm in 42 eyes (22 %). We commenced topical artificial tears therapy for all of them and additional topical cyclosporin A for 30 of them. Cyclosporin A therapy was ceased and restarted according to the clinical courses of the patients.

The frequency of women were significantly higher than that of men (P = 0.003). OSDI scores were under 25 in 87 (91 %) patients and between 25 and 30 in 9 (9 %) patients preoperatively. However, postoperatively in 1st week, it was under 25 in 15 (16 %) patients, between 25 and 30 in 33 (34 %) patients, between 30 and 40 in 21 (22 %) patients and between 40 and 50 in 27 (28 %) patients. In postoperative 1st month, it was under 25 in 30 (31 %) patients, between 25 and 30 in 39 (41 %) patients and between 30 and 40 in 27 (28 %) patients. In postoperative 3rd month it was under 25 in 84 (88 %) patients and between 25 and 30 in 12 (12 %) patients. In postoperative 6th month it was under 25 in 90 (94 %) patients and between 25 and 30 in 6 (6 %) patients. According to Oxford Schema, preoperatively only 15 eyes had grade 2 fluorescein staining (7 %). But postoperatively on 1st day, 36 eyes had grade 2 (18 %), 24 eyes had grade 3 (12 %) and 12 eyes had grade 4 (6 %) fluorescein staining pattern. In 1st week 24 eyes had grade 2
and 12 eyes had grade 3 (6 %) staining. In 1st month 18 eyes had grade 2 (9 %) and 6 eyes had grade 3 (3 %) staining. In 3rd month, only 6 eyes had grade 2 staining pattern (3 %). The mean preoperative BUT value was 11.65 ± 2.31 (SD) (7–16) seconds. Postoperative 1st day value was 7.60 ± 1.24 (SD) (5–11), 1st week value 7.03 ± 0.97 (SD) (5–9), 1st month value 7.42 ± 0.79 (SD) (6–8), 3rd month value 11.76 ± 2.08 (SD) (9–16), 6th month value 12.01 ± 2.05 (SD) (9–16), 1st year value 11.85 ± 2.01 (SD) (8–17) and 2nd year value was 11.95 ± 1.92 (SD) (9–17) seconds. In comparison with preoperative value, the 1st day, 1st week and 1st month values were significantly lower (P < 0.001, P < 0.001, P < 0.001), however 3rd month, 6th month, 1st year and 2nd year values were not significantly different from preoperative value (P = 0.441, P = 0.078, P = 0.145, P = 0.125). This is shown in Fig. 1.

The mean preoperative ST1 value was 6.39 ± 1.42 (SD) (4–9) mm. Postoperative 1st day value was 4.59 ± 1.06 (SD) (3–7), 1st week value 4.45 ± 0.95 (SD) (2–6), 1st month value 4.50 ± 1.00 (SD) (3–6), 3rd month value 6.42 ± 1.31 (SD) (4–9), 6th month value 6.46 ± 1.28 (SD) (4–10), 1st year value 6.59 ± 1.38 (SD) (4–9) and 2nd year value was 6.54 ± 1.29 (SD) (4–9) mm. In comparison with preoperative value, 1st day, 1st week and 1st month values were significantly lower (P < 0.001, P < 0.001, P < 0.001), however 3rd month, 6th month, 1st year and 2nd year values were not significantly different from preoperative value (P = 0.748, P = 0.439, P = 0.091, P = 0.214). This is shown in Fig. 2.

By the way, the subjective symptoms of the patients related to dry eye increased postoperatively. But after postoperative 1st month, their complaints decreased gradually. As it was seen; fluorescein staining, BUT and ST1 were impaired up to 1st month postoperatively, however, after 1st month, they improved and they returned to preoperative levels in 3rd month (Additional file 1).

Discussion

Cornea is innervated by long ciliary nerves of ophthalmic branch of the fifth (trigeminal) nerve. In normal conditions, these nerves send afferent stimuli to brain stem and parasympathetic and sympathetic signals stimulate lacrimal gland for tear production and secretion [11–13]. For normal blinking and tearing reflexes, intact corneal innervation is necessary. Damage of this circuit causes dry eye. Surgical procedures like PRK, LASIK, extracapsular cataract extraction and phacoemulsification causing denervation of cornea result in decreased blinking and reduction in tear production thus leading to increased epithelial permeability, decreased epithelial metabolic activity and impaired epithelial wound healing [14, 15]. Inflammatory mediators released after corneal incisions may also change the actions of the corneal nerves and reduce corneal sensitivity and result in tear film instability [16, 17]. In healing process, neural growth factor is released to regenerate the subepithelial corneal axon, this process is completed approximately within 1 month and this recovery of the nerves may explain why dry eye signs and symptoms are prominent early after surgery and improve thereafter [16]. This is in accordance with our study. Incision site is larger in LASIK and extracapsular cataract extraction in comparison with phacoemulsification, hence, dry eye signs and symptoms are more prominent and last longer in these patients [18, 19].

Vigorous irrigation of the cornea intraoperatively and ocular surface manipulation deteriorate tear film stability and may reduce goblet cell density and thus cause
shortened BUT postoperatively [6, 20]. Exposure to microscope light may also aggravate dry eye symptoms postoperatively [15]. In our study also, BUT values decreased postoperatively.

The use of topical anesthesia, topical eye drops containing preservatives like benzalkonium chloride administered preoperatively and postoperatively may cause tear film instability and decrease the number of mucin expressing cells and lead to dry eye postoperatively [21, 22]. We did not use any topical eye drops containing preservatives postoperatively for our patients not to increase dry eye symptoms.

We did not divide the patients into subgroups according to their degree of dry eye severity. We evaluated the patients as one group statistically. The use of means of this group’s test results might mask subgroups which might behave differently from the group as a whole. That was our limitation in this study.

Khanal et al. [9] reported that deterioration in corneal sensitivity and tear physiology was seen immediately after phacoemulsification. Corneal sensitivity didn’t return to preoperative levels until 3 months postoperatively whereas the tear functions recovered within 1 month. Kasetsuwan et al. [20] reported that, signs and symptoms of dry eye occurred as early as 7 days post-phacoemulsification and the severity pattern improved over time. In our study also, dry eye test values returned to preoperative values after postoperative 3rd month.

Oh et al. [19] reported that, the decrease in goblet cell density, which was correlated with operation time, had not recovered at 3 months after cataract surgery, therefore, microscopic ocular surface damage during cataract surgery seems to be one of the pathogenic factors that causes ocular discomfort and dry eye syndrome after cataract surgery. Han et al. [23] reported that Meibomian gland function may be altered without accompanying structural changes after cataract surgery.

Movahedan et al. [24] reported that, maintaining a healthy ocular surface is essential for achieving the best visual outcome in cataract patients. Ocular surface preparation is beneficial not only in patients with established ocular surface disease, but also in those with minimal signs or symptoms of surface disease. Chung et al. [25] suggested that, cyclosporine 0.05 % can be an effective treatment for dry eye after cataract surgery.

Conclusion
Phacoemulsification surgery may aggravate the signs and symptoms of dry eye and affect dry eye test values in chronic dry eye patients in short-term. However, in long-term, signs and symptoms of dry eye decrease and dry eye test values return to preoperative values.

Additional file

Additional file 1: STROBE Statement.

Abbreviations
SD: Standard Deviation; OSDI: Ocular Surface Disease Index; BUT: Break-up Time; ST1: Schirmer Test 1.

Competing interests
The authors declare that they have no competing interest.

Authors’ contributions
SC conceived the idea of the study, performed all examinations and operations and wrote the article and performed the statistical analysis. EM, NOA, YFC, ZD and HIY helped with design and methodology of the study. All authors read and approved the final manuscript.
Acknowledgments
The authors report no conflicts of interest. There is no source of funding to disclose. The authors alone are responsible for the content and writing of the paper.

Author details
1Ophthalmology Clinics, Turkish Red Crescent Hospital, Konya, Turkey.
2Department of Neurology, Dumlupinar University, Faculty of Medicine, Kütahya, Turkey.
3Department of Ophthalmology, Faculty of Medicine, Mevlana University, Konya, Turkey.
4Department of Ophthalmology, Atatürk Training and Research Hospital, Ankara, Turkey.
5Konya Eye Centre Hospital, Konya, Turkey.
6Turkish Red Crescent Hospital (Kızilay Hastanesi), Ophthalmology Clinics, Sukan Mah. Taskapu Medrese Sok. No:15, Meram, 42200 Konya, Turkey.

Received: 29 January 2015 Accepted: 16 June 2015
Published online: 30 June 2015

References
1. Sheppard JD. Guidelines for the treatment of chronic dry eye disease. Manag Care. 2003;12(12 Suppl):20–5.
2. Apostol S, Filip M, Dragne C, Filip A. Dry eye syndrome; etiological and therapeutic aspects. Oftalmologia. 2003;59:28–31.
3. Shoja MR, Besharat MR. Dry eye after LASIK for myopia: incidence and risk factors. Eur J Ophthalmol. 2007;17:1–6.
4. Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008;85:668–74.
5. De Paiva CS, Chen Z, Koch DD, Hamill MB, Manuel FK, Hassan SS, et al. The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol. 2006;141:438–45.
6. Li XM, Hu L, Hu J, Wang W. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007;26 Suppl 1:1516–20.
7. Garcia-Catalan MR, Jerez-Olivera E, Benitez-Del-Castillo-Sanchez JM. Dry eye and quality of life. Arch Soc Esp Oftalmol. 2009;84:451–8.
8. Hardten DR. Dry eye disease in patients after cataract surgery. Cornea. 2008;27:855.
9. Khanal S, Tomlinson A, Esakovitz L, Bhatt P, Jones D, Nabili S, et al. Changes in corneal sensitivity and tear physiology after phacoemulsification. Ophthalmic Physiol Opt. 2008;28:127–34.
10. Albietz JM, Lenten LM. Management of the ocular surface and tear film before, during, and after laser in situ keratomileusis. J Refract Surg. 2004;20:62–71.
11. Dart DA. Dysfunctional neural regulation of lacrimal gland secretion and its role in the pathogenesis of dry eye syndromes. Ocul Surf. 2004;2:76–91.
12. Donnenfeld ED, Solomon K, Perry HD, Doshy SJ, Ehrenhaus M, Solomon R, et al. The effect of hinge position on corneal sensation and dry eye after LASIK. Ophthalmology. 2003;110:1023–9.
13. Al-Aqaba MA, Fares U, Suleman H, Lowe J, Dua HS. Architecture and distribution human corneal nerves. Br J Ophthalmol. 2010;94:784–9.
14. Gayton JL. Etiology, prevalence and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405–12.
15. Cho YK, Kim MS. Dry eye after cataract surgery and associated intraoperative risk factors. Korean J Ophthalmol. 2009;23:65–73.
16. Belmonte C, Acosta MC, Gallar J. Neural basis of sensation in intact and injured corneas. Exp Eye Res. 2004;78:513–25.
17. Sanchez MA, Aniola-Villalobo P, Torralbo-Jimenez P, Giron N, de la Heras B, Herrero Varell R, et al. The effect of preservative-free HP-Guar on dry eye after phacoemulsification: a flow cytometric study. Eye. 2010;24:1331–7.
18. Hoffman RS, Fine IH, Packer M. New phacoemulsification technology. Curr Opin Ophthalmol. 2005;16:38–43.
19. Oh T, Jung Y, Chang D, Chang D, Kim J, Kim H. Changes in tear film and ocular surface after cataract surgery. Jpn J Ophthalmol. 2012;56:113–8.
20. Kasetsuwan N, Satipakul V, Changul T, Jarjakosol S. Incidence and pattern of dry eye after cataract surgery. PLoS One. 2013;8:1–6.
21. Nistor MC, Nistor C. Clinical correlations between dry eye and cataract surgery. Oftalmologia. 2007;51:79–82.
22. Ishibashi T, Yoko K, Kinosita S. Comparison of short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486–90.
23. Han KE, Yoon SC, Ahn JM, Nam SM, Stulting RD, Kim EK, et al. Evaluation of dry eye and meibomian gland dysfunction after cataract surgery. Am J Ophthalmol. 2014;157:1144–50.
24. Movahedian A, Djallilian AR. Cataract surgery in the face of ocular surface disease. Curr Opin Ophthalmol. 2012;23:68–72.
25. Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05 % on dry eye after cataract surgery. Korean J Ophthalmol. 2013;27:167–71.

www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit